Výsledky vyhledávání - "Monette A. Aujay"

Supplementary Figure 1 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome

Autor: Mark K. Bennett, Christopher J. Molineaux, Tina M. Woo, Marcy K. Vallone, Congcong M. Sun, Mark S. Smyth, Kevin D. Shenk, Francesco Parlati, Evan R. Lewis, Guy J. Laidig, Jing Jiang, Mark N. Ho, Maya Dajee, Tonia J. Buchholz, Monette A. Aujay, Christopher J. Kirk, Susan D. Demo

Supplementary Figure 1 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a101c8883eaf41acd7d210a2605a14a
https://doi.org/10.1158/0008-5472.22367433.v1

Zobrazit plný text záznamu

Supplementary Figure 2 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome

Supplementary Figure 2 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6bf03b50a24a2f24a2702fa914794b3
https://doi.org/10.1158/0008-5472.22367430.v1

Zobrazit plný text záznamu

Data from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome

Clinical studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and non-Hodgkin's lymphoma. However, significant toxicities have restricted the intensity of bortezomib dosing. Here we descr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47fe217774fa4900e95086b10a5be1f2
https://doi.org/10.1158/0008-5472.c.6495546.v1

Zobrazit plný text záznamu

Elvn-001, a Next Generation ATP-Competitive ABL1 Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia

Autor: Stefan D Gross, Christopher A. Eide, Michael R Burkard, Anna Reister Schultz, Monette A Aujay, Samuel Kintz, Brian J. Druker, Joseph P Lyssikatos

Publikováno v: Blood. 140:3095-3096

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86db53347e3725aa72668b1c082fd869
https://doi.org/10.1182/blood-2022-162700

Zobrazit plný text záznamu

PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo

Autor: Ajita V, Singh, Madhavi, Bandi, Monette A, Aujay, Christopher J, Kirk, David E, Hark, Noopur, Raje, Dharminder, Chauhan, Kenneth C, Anderson

Publikováno v: British journal of haematology. 152(2)

PR-924 is an LMP-7-selective tripeptide epoxyketone proteasome inhibitor that covalently modifies proteasomal N-terminal threonine active sites. In the present study, we show that PR-924 inhibits growth and triggers apoptosis in multiple myeloma (MM)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ff6bee37764d51972056477a4feb1fd3
https://pubmed.ncbi.nlm.nih.gov/21114484

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání